BT Must Block Piracy Links; Myriad DNA Patents Are Good; There’s FDA App Guidance For That – What’s Trending in Tech Law

Screen shot 2011-07-29 at 1.23.23 PM.pngFor your Friday reading pleasure: a handful of news items recently trending in JD Supra’s Tech and IP Law channels:

- British High Court Rules: ISP British Telecommunications Must Block Piracy Links

In what is being described as a “benchmark ruling” the London high court decided that the United Kingdom’s largest internet service provider, British Telecommunications (BT), must block links to prevent its users from downloading pirated movies, music, and the like. A raftload of media heavyweights (including Paramount Pictures, Universal, Warner Bros., Disney, 20th Century Fox, and others) sued “to block or at least impede access by BT’s subscribers to a website currently located at www.newzbin.com” in their ongoing efforts to curtail piracy and copyright infringement. The test case appears to have worked, at least in the courts.

Read the Honorable Mr. Justice Arnold’s July 28, 2011, landmark decision in 20th Century Fox et al. v British Telecommunications in its entirety. (For additional background on the story, see British Court Rules ISP must block pirate site from The Globe and Mail.)

- Isolated DNA is Patentable: Federal Circuit Reverses District Court Myriad Decision

In a long awaited decision the Federal Circuit handed down its ruling today in ASSOCIATION FOR MOLECULAR PATHOLOGY v. MYRIAD. Here’s the summary from JD Supra contributor, IP attorney Kevin Buckley: “…the Court reversed the district court’s decision that Myriad’s
composition claims to ‘isolated’ DNA molecules cover patent-ineligible
products of nature under § 101 since the molecules as claimed do not
exist in nature. The Court also reversed the district court’s decision
that Myriad’s method claim to screening potential cancer therapeutics
via changes in cell growth rates is directed to a patent-ineligible
scientific principle. However, the Court affirmed the district court’s
decision that Myriad’s method claims directed to ‘comparing’ or ‘analyzing’ DNA sequences are patent ineligible; such claims include no
transformative steps and cover only patent-ineligible abstract, mental
steps.”

Read the entire decision here: ASSOCIATION FOR MOLECULAR PATHOLOGY v. MYRIAD – Federal Circuit decision reversing District Court under Section 101 – Isolated DNA is Patentable.

- Medical Mobile App? There’s FDA Guidance for That!

We’ve seen increased interest in the Federal Drug Administration’s July 21 draft guidance on certain medial mobile apps which, according to the FDA, pose similar risks as other regulated medical devices. Beyond the scope of the FDA? You decide:

Read current law firm commentary and analysis on the mobile medical app FDA draft guidance - more will be added as it comes in.

- Anything else?

Indeed: bonus material for reading this far. Posted yesterday, an interesting case study/interview with Fenwick & West entertainment, consumer technology and intellectual property attorney Jennifer Stanley:

New Media, New Rules: Copyright Strategies in the Age of Apps.

Enjoy your weekend and we’ll see you online:

Follow Tech Law on LinkedIn | Twitter | Facebook | JD Supra